# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k103744   
B. Purpose for Submission: New Device   
C. Measurand: Quality control material for Hemoglobin A1c (HbA1c)   
D. Type of Test: Not applicable   
E. Applicant: Quantimetrix Corporation   
F. Proprietary and Established Names: Dropper A1c Diabetes Control   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JJX</td><td rowspan=1 colspan=1>Class I,reserved</td><td rowspan=1 colspan=1>21 CFR § 862.1660, Quality controlmaterial (assayed and unassayed).</td><td rowspan=1 colspan=1>Clinical Chemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use: The Quantimetrix Dropper A1c Diabetes Control is intended for the quality control of laboratory procedures used to quantitate HbA1c.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: Beckman Coulter Synchron, Ortho-Clinical Vitros, Primus Corporation PDQ/Ultra, Roche Cobas Integra, Roche Diagnostics Hitachi, Siemens Healthcare Diagnostics DCA 2000/Vantage and Siemens Healthcare Diagnostics Dimension

# I. Device Description:

The Dropper A1c Diabetes Control consists of two levels; one level represents Hb1A1c near the threshold level and one in the pathological range. The controls are supplied as a ready to use frozen liquid, requiring no reconstitution or dilution. They are prepared in a whole blood matrix fortified to target levels with reagent grade chemicals added to achieve the two levels. Preservatives have been added to inhibit microbial growth.

# J. Substantial Equivalence Information:

<table><tr><td>Predicate device name</td><td>Predicate 510(k) number</td></tr><tr><td>MAS Diabetes Control</td><td>k023307</td></tr></table>

Comparison with predicate:   

<table><tr><td rowspan=1 colspan=3>Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device(k023307)</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Assayed quality controlmaterial for monitoringGlycoslated Hemoglobin(A1c) assay procedures.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Hemoglobin A1c</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Frozen liquid whole blood</td></tr><tr><td rowspan=1 colspan=1>Number of Levels</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Two</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Reagent grade chemicals andconstituents of human origin</td><td rowspan=1 colspan=1>Pure chemicals andconstituents of human origin</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Closed Vial:3 years at -10 to -30°180 days at 2 to 8°COpen Vial:180 days at 2 to 8°C21 days at 18 to 25°C</td><td rowspan=1 colspan=1>Closed Vial:2 years at -15 to -25°C60 days at 2 to 8°COpen Vial:21 days at 2 to 8°C</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable): None were referenced.

L. Test Principle: Not applicable

M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

Not applicable

b. Linearity/assay reportable range: Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability

The Hemoglobin A1c material is traced to a National Glycohemoglobin Standardization Program (NGSP) Certified testing method performed on Siemens Dimension RxL and DCA $2 0 0 0 +$ analyzers.

# Value Assignment

The Dropper A1c Diabetes Control consists of two levels of Hemoglobin A1c (Hb1A1c); one level near the threshold level (Level 1) and one in the pathological range (Level 2). Value assignment is performed by running each level once per day on each analyzer for three days by two or more different operators (six or more tests per analyzer). All values for each analyzer are inputted and the range for each level is set at $\pm 2 0 \%$ from the calculated mean value. The mean and ranges for Level 1 and 2 are provided for each analyzer in the table below.

<table><tr><td rowspan=2 colspan=1>Analyzer</td><td rowspan=1 colspan=2>Level 1</td><td rowspan=1 colspan=2>Level 2</td></tr><tr><td rowspan=1 colspan=1>Mean (%)</td><td rowspan=1 colspan=1>ExpectedRange (%)</td><td rowspan=1 colspan=1>Mean (%)</td><td rowspan=1 colspan=1>ExpectedRange (%)</td></tr><tr><td rowspan=1 colspan=1>Beckman CoulterSynchron</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>4.7 - 7.1</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>8.2  12.3</td></tr><tr><td rowspan=1 colspan=1>Ortho-Clinical Vitros</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>4.9 - 7.3</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>8.3 - 12.5</td></tr><tr><td rowspan=1 colspan=1>Primus CorporationPDQ/Ultra</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>6.6  9.9</td><td rowspan=1 colspan=1>17.7</td><td rowspan=1 colspan=1>14.1 - 21.2</td></tr><tr><td rowspan=1 colspan=1>Roche Cobas Integra</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>4.9 - 7.3</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>8.3 - 12.4</td></tr><tr><td rowspan=1 colspan=1>Roche DiagnosticsHitachi</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>4.1 - 6.2</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>12.3 - 18.4</td></tr><tr><td rowspan=1 colspan=1>Siemens HealthcareDiagnostics DCA2000/Vantage</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>4.8 - 7.1</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>7.1 - 10.6</td></tr><tr><td rowspan=1 colspan=1>Siemens HealthcareDiagnostics Dimension</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>4.9 - 7.4</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>8.3  12.4</td></tr></table>

<table><tr><td colspan="1" rowspan="2">Analyzer</td><td colspan="2" rowspan="1">Level 1</td><td colspan="2" rowspan="1">Level 2</td></tr><tr><td colspan="1" rowspan="1">Mean(mmol/mol)</td><td colspan="1" rowspan="1">ExpectedRange(mmol/mol)</td><td colspan="1" rowspan="1">Mean(mmol/mol)</td><td colspan="1" rowspan="1">ExpectedRange(mmol/mol)</td></tr><tr><td colspan="1" rowspan="1">Beckman CoulterSynchron</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">28 - 54</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">66 - 111</td></tr><tr><td colspan="1" rowspan="1">Ortho-Clinical Vitros</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">30 - 56</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">67 - 113</td></tr><tr><td colspan="1" rowspan="1">Primus CorporationPDQ/Ultra</td><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">49 - 85</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">131 - 208</td></tr><tr><td colspan="1" rowspan="1">Roche Cobas Integra</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">30 - 56</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">67 - 112</td></tr><tr><td colspan="1" rowspan="1">Roche DiagnosticsHitachi</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">21 - 44</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">111 - 178</td></tr><tr><td colspan="1" rowspan="1">Siemens HealthcareDiagnostics DCA2000/Vantage</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">29 - 54</td><td colspan="1" rowspan="1">73</td><td colspan="1" rowspan="1">54 - 92</td></tr><tr><td colspan="1" rowspan="1">Siemens HealthcareDiagnostics Dimension</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">30 - 57</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">67 - 112</td></tr></table>

# Stability:

The closed vial stability was evaluated in accelerated and real-time stability studies. Unopened vials stored at $2 5 \mathrm { { ^ \circ C } }$ (test material) or $3 7 ^ { \circ } \mathrm { C }$ (test material) were tested against unopened vials stored at $- 1 0 ^ { \circ } \mathrm { C }$ to $- 3 0 ^ { \mathrm { { o } } } \mathrm { { C } }$ (reference material) at predetermined time points during a 6 month interval. Based upon accelerated study data, the sponsor claims closed vial stability of 180 days at 2 to $8 ^ { \circ } \mathrm { C }$ . Real-time stability study is on-going.

The open vial stability was evaluated in accelerated and real-time stability studies. Opened vials stored at $3 7 ^ { \circ } \mathrm { C }$ (test material) were tested in duplicate against unopened vials stored at $- 1 0 ^ { \circ } \mathrm { C }$ to $- 3 0 ^ { \circ } \mathrm { C }$ (reference material) at predetermined time points during a 6 month interval. In a second real-time stability study, opened vials stored at $2 5 ^ { \circ } \mathrm { C }$ (test material) were tested in duplicate against unopened vials stored at $- 1 0 ^ { \circ } \mathrm { C }$ to $- 3 0 ^ { \mathrm { { o } } } \mathrm { { C } }$ (reference material) at five time points during a 1 month interval. Based upon accelerated and a real-time stability studies, the sponsor claims open vial stability of 180 days at 2 to $\underline { { 8 ^ { \circ } \mathrm { C } } }$ or 21 days at 18 to $2 5 ^ { \circ } \mathrm { C }$ .

d. Detection limit: Not applicable e. Analytical specificity: Not applicable

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: The expected values on each analyzer are presented in the labeling.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.